Amarin Corp
Executivos
Veja o organograma con seus 15 executivos principais
Biografias mais buscadas da Amarin Corp
- Aaron Berg, President and Chief Executive Officer
- Paul Cohen, Director
- Oliver O'Connor, Independent Director
Recentes movimentos de executivos em Amarin Corp
- Patrick Holt, Chief Executive Officer and Director, deixou a Companhia (Notícia publicada em 5 de junho de 2024).
- Aaron Berg antes Executive Vice President and President, US, foi promovido a President and Chief Executive Officer (Notícia publicada em 5 de junho de 2024).
- Jonathan Provoost ingressará na Companhia como Executive Vice President and Chief Legal & Compliance Officer em 15 de nov. de 2023 (Notícia publicada em 1 de novembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Amarin Corp.
Farmacêutica
Amarin Corp possui 1.853 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).
Popular M&A news in Farmacêutica
- LakeShore Biopharma mudará seu nome para LakeShore Biopharma em May 24, 2024. (publicado em 25 de maio de 2024).
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Amarin Corp
- Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update | Amarin Corporation plc
- Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022 | Amarin Corporation plc
- NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales | Amarin Corporation plc
- REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo | Amarin Corporation plc
- Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl) | Amarin Corporation plc
- Press Releases | Amarin Corporation plc
- Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business | Amarin Corporation plc
- Amarin Appoints Tom Reilly as New Chief Financial Officer | Amarin Corporation plc
- Amarin Announces Appointment of New Directors and Board Leadership Changes | Amarin Corporation plc
- Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs | Amarin Corp
- View more press releases Close
Redes sociais sobre Amarin Corp
- Amarin Corp na Wikipedia, Google News e Yahoo Finance
- Amarin Corp na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Aaron Berg 
Ligue para a Amarin Corp em +353 ...
